HAEMONETICS CORP 4
4 · HAEMONETICS CORP · Filed Feb 19, 2014
Insider Transaction Report
Form 4
HANLON SUSAN M
VP Finance
Transactions
- Exercise/Conversion
Common Stock
2014-02-18$26.47/sh+3,690$97,674→ 20,595 total - Sale
Common Stock
2014-02-18$39.00/sh−3,690$143,910→ 16,905 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2014-02-18$39.00/sh−3,690$143,910→ 11,000 totalExercise: $26.47From: 2010-10-27Exp: 2016-10-27→ Common Stock (3,690 underlying)
Holdings
- 16,882
Non-Qualified Stock Option (right to buy)
Exercise: $39.05From: 2013-10-24Exp: 2019-10-24→ Common Stock (16,882 underlying) - 22,348
Non-Qualified Stock Option (right to buy)
Exercise: $27.50From: 2011-10-27Exp: 2017-10-27→ Common Stock (22,348 underlying) - 18,456
Non-Qualified Stock Option (right to buy)
Exercise: $41.66From: 2014-10-23Exp: 2023-10-23→ Common Stock (18,456 underlying) - 12,500
Performance Shares
Exercise: $0.00From: 2017-03-31Exp: 2017-12-31→ Common Stock (12,500 underlying) - 20,726
Non-Qualified Stock Option (right to buy)
Exercise: $30.67From: 2012-10-25Exp: 2018-10-25→ Common Stock (20,726 underlying)
Footnotes (3)
- [F1]Pursuant to a 10b5-1 Plan.
- [F2]Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
- [F3]Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).